Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ExonHit, a developer of therapeutic and diagnostic products, has extended its drug discovery collaboration with Allergan Sales until December 2013.
Subscribe to our email newsletter
The objective of extending collaboration is to identify, develop and commercialize drugs to treat neurodegenerative diseases, ophthalmology and pain.
Exonhit CEO Loic Maurel said the collaboration has created value for both organizations, and they are optimistic that it will continue to build upon recent successes and advance additional existing preclinical programs into clinical development.
Under the collaboration, Allergan has granted EHT/AGN 0001(AGN-209323) sub-license to Bristol-Myers Squibb Company.
EHT/AGN 0001 is a Phase II, orally bio-available small molecule which is in clinical development to treat neuropathic pain.
The collaboration agreement between Allergan and Bristol-Myers also covered EHT/AGN 0002 and associated back-up compounds.